Loading stock data…
Agilent Technologies, Inc. (A)
$138.57-1.17 (-0.84%)
Market ClosedLast close Jul 24
Agilent Technologies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agilent Technologies, Inc. in the Healthcare sector is trading at $138.57 with a market capitalization of $36.9B. Wall Street consensus targets $159.32 (19 analysts), implying a +15.0% move over the next 12 months. The stock is currently 14% below its 52-week high of $160.27, remaining 6.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.83B↑ | $1.80B↓ | $1.86B↑ | $1.74B↑ | $1.67B |
| Gross Profit | $990.00M↑ | $946.00M↓ | $990.00M↑ | $888.00M↑ | $866.00M |
| Operating Income | $399.00M↑ | $353.00M↓ | $443.00M↑ | $360.00M↑ | $300.00M |
| Net Income | $339.00M↑ | $305.00M↓ | $434.00M↑ | $336.00M↑ | $215.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and App...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$36.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.24
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.55%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.85%
Volume
Today's trading volume
1.13M
Recent News
Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test
In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. This approval deepens Agilent’s role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in...
What to Expect From Agilent Technologies' Q3 2026 Earnings Report
Agilent Technologies is poised to release its third-quarter results soon, and analysts are projecting a single-digit earnings rise.
Can GE HealthCare Sustain Growth in Q2 Amid Persistent Cost Headwinds?
GE HealthCare heads into Q2 earnings season with solid revenue drivers, but inflation and tariff costs may keep margins under pressure before an expected second-half recovery.
Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?
BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.
1 Healthcare Stock to Research Further and 2 We Avoid
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.